Roderick Terry Bronson, D.V.M.
This page shows the publications co-authored by Roderick Bronson and Joan Brugge.
Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer. Breast Cancer Res. 2020 11 30; 22(1):132.
Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo. Mol Cancer Ther. 2019 06; 18(6):1115-1126.
Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance. Cancer Cell. 2018 06 11; 33(6):985-1003.e7.
Erratum: Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo. NPJ Breast Cancer. 2017; 3:38.
Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo. NPJ Breast Cancer. 2017; 3:18.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.